摘要:
An apparatus management device, which is connected via a network to an apparatus, includes a storage unit configured to store a default value for a parameter of the apparatus and a table including coefficients associated with counter values indicating operational status of the apparatus; an apparatus information obtaining unit configured to obtain apparatus information including a counter value indicating the operational status from the apparatus; a parameter value calculation unit configured to obtain one of the coefficients that corresponds to the counter value in the obtained apparatus information by referring to the table, and to calculate an update value for the parameter of the apparatus by multiplying the default value by the one of the coefficients; and a setting unit configured to set the parameter of the apparatus at the update value.
摘要:
An information processing apparatus is configured to communicate with a device through a first communication path and to communicate, through a second communication path, with a device management apparatus configured to manage the device, and to include a detection part, a transmission part, a reception part, and an acquisition part. The detection part detects connection with the device through the first communication path. The transmission part transmits predetermined notification including identification information of the information processing apparatus to the device management apparatus, when the connection with the device is detected. The reception part receives a device information acquisition request from the device management apparatus based on the predetermined notification. The acquisition part acquires device information of the device. The transmission part transmits, to the device management apparatus, response to acquisition of the device information including the identification information of the information processing apparatus and the device information.
摘要:
Quinazolinone compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the quinazolinone compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the quinazolinone compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.
摘要:
Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF-1R.
摘要:
The present invention relates to new indole and benzimidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula:
摘要:
The present invention relates to new substituted quinoline compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula:
摘要:
The present invention relates to compounds that are useful for treating cellular proliferative diseases, for treating disorders mediated, at least in part, by KSP, and for inhibiting KSP. The invention also related to pharmaceutical compositions comprising such compounds, methods of treating cancer by the administration of such compositions, and processes for the preparation of the compounds. Compounds of the invention have the following formula: formula (I).
摘要:
The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula: